ACADIA Pharmaceuticals (NASDAQ:ACAD) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight commercial momentum from its two marketed products, outline a slate of clinical milestones across neurology and rare disease, and discuss investments in capabilities such as a